This project is dedicated to establishing non-invasive diagnostic tools as the cornerstone of early disease detection and preventative healthcare across Europe. Using Fibronostics‚ LIVERFAST and LiverSTAT as pilot products, the initiative applies scenario planning and strategic design to create a comprehensive market entry roadmap. By aligning these diagnostics with Europe’s healthcare evolution, the project envisions a seamless introduction of non-invasive tools that cater to increasing consumer health awareness and meet stringent regulatory standards.

The approach combines detailed scenario analysis with strategic planning to address key market factors, including clinical partnerships, pricing, and public education. The goal is to foster widespread adoption by crafting tailored messaging for diverse healthcare environments—from specialized liver clinics to general practice settings. Through predictive insights into healthcare trends and technology adoption, the project identifies optimal pathways for deployment, ensuring that these diagnostic tools can meet Europe’s high regulatory demands while remaining accessible and effective for a broad user base.

This roadmap is designed to guide the tools from regulatory approval to market readiness, emphasizing user-friendly accessibility and educational outreach to drive patient and provider engagement. Ultimately, the project not only prepares for the immediate entry of LIVERFAST and LiverSTAT but also sets a scalable framework for the sustained growth of non-invasive diagnostics in Europe, positioning them as critical components of future healthcare infrastructure.

In collaboration with:
Marie Köhle